Table 1:

Baseline patient characteristics and treatment details

Characteristic	Patients (n=51)
Median age [IQR] - yr	64 [59-71]
Sex - no. (%)
Female	29 (57%)
Male	22 (43%)
Cigarette smoking status - no. (%)
Former or current	43 (84%)
Never	8 (16%)
Histology - no. (%)
Adenocarcinoma	36 (71%)
Non-adenocarcinoma	8 (16%)
Small cell lung cancer	7 (14%)*
PD-L1 expression by TPS - no./total no. (%)
0%	11/33 (33%)
1-49%	7/33 (21%)
≥ 50%	15/33 (45%)*
Unknown or not applicable	18
Line of therapy - no. (%)
1 or early stage	28 (55%)
2	13 (25%)
3 or higher	10 (20%)
Past medical history - no. (%)
Autoimmune condition^	7 (14%)
Prior thoracic radiation therapy	11 (22%)
Treatment - no. (%)
Anti-PD-(L)1 monotherapy	25 (49%)
Anti-PD-(L)1+CTLA-4 combination	19 (37%)
Anti-PD-(L)1+chemotherapy	5 (10%)
Anti-PD-(L)1+other (non-chemotherapy)	2 (4%)

^*Percentages may not add up to 100 due to rounding

^{^}Autoimmune condition including thyroiditis (n=3), inflammatory bowel disease (n=2), psoriasis (n=2), reactive airways disease (n=1), type 2 diabetes (n=1). IQR = interquartile range, PD-(L)1 = programmed cell death protein (ligand) 1, TPS = tumor proportion score, CTLA-4 = cytotoxic T-lymphocyte-associated protein 4